Menu Search
Equities

Uni-Bio Science Group Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
690:HKG.HS

Uni-Bio Science Group Ltd

Actions
  • Price (HKD)0.115
  • Today's Change0.001 / 0.88%
  • Shares traded1.74m
  • 1 Year change+105.36%
  • Beta0.1235
Data delayed at least 15 minutes, as of Feb 13 2026 08:08 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Uni-Bio Science Group Ltd is an investment company mainly engaged in the manufacture and sales of pharmaceutical products. The Company operates its business through three segments. Biological Pharmaceutical Products segment is mainly engaged in the manufacture and sale of biological pharmaceutical products. Chemical Pharmaceutical Products segment is mainly engaged in the manufacture and sale of chemical pharmaceutical products. Pipeline Products segment is mainly engaged in the research and development of pharmaceutical products.

  • Revenue in HKD (TTM)589.59m
  • Net income in HKD91.35m
  • Incorporated2001
  • Employees504.00
  • Location
    Uni-Bio Science Group Ltd13/F, Public Bank Centre,120 Des Voeux Road Central, Central Hong KongHKG
  • Phone+852 31023232
  • Fax+852 31023737
  • Websitehttps://www.uni-bioscience.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.